Literature DB >> 2559041

Muramyl peptides confer hepatoprotection against murine viral hepatitis.

K N Masihi1, H Kröger, W Lange, L Chedid.   

Abstract

The hepatoprotection induced by synthetic muramyl peptides was investigated using a model of lethal murine mouse hepatitis MHV-3 virus infection. MDP and a nonpyrogenic analog, Murametide, inhibited the steep elevation of serum transaminases induced by MHV-3 irrespective of whether the immunomodulators were administered before or after the infection. A significant proportion of MDP or Murametide-treated animals, in contrast to controls, survived the MHV-3 infection. The histopathological examination of the liver revealed marked necrosis of the hepatic parenchymal cells and infiltration of the inflammatory cells in controls but not in MDP-treated animals.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2559041      PMCID： PMC7173131          DOI： 10.1016/0192-0561(89)90109-4

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN： 0192-0561


  21 in total

1.  Enhancement in anti-Semliki Forest virus activity of ds RNA by a muramyl dipeptide.

Authors:  C X George; R K Jain; C M Gupta; N Anand
Journal:  FEBS Lett       Date:  1986-05-05       Impact factor: 4.124

2.  Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.

Authors:  Y Yamamura; C Ishihara; N Hamada; K Yamamoto; I Azuma
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-01

3.  Protective effect of muramyl dipeptide analogs in combination with trehalose dimycolate against aerogenic influenza virus and Mycobacterium tuberculosis infections in mice.

Authors:  K N Masihi; W Brehmer; W Lange; E Ribi; S Schwartzman
Journal:  J Biol Response Mod       Date:  1984-12

4.  Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection.

Authors:  K N Masihi; W Brehmer; W Lange; E Ribi
Journal:  Int J Immunopharmacol       Date:  1983

5.  Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in squalane droplets.

Authors:  K N Masihi; W Lange; B Rohde-Schulz
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.

Authors:  J E Talmadge; M Schneider; M Collins; H Phillips; R B Herberman; R H Wiltrout
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

7.  Immune responses to hepatitis B virus and tuberculosis infections in Southeast Asian refugees.

Authors:  K A McGlynn; E D Lustbader; W T London
Journal:  Am J Epidemiol       Date:  1985-12       Impact factor: 4.897

8.  The protection from hepatotoxicity of some compounds by the synthetic immunomodulator muramyl dipeptide (MDP) in rat hepatocytes and in vivo.

Authors:  H Farghali; Z Machková; L Kameníková; I Jankü; K Masek
Journal:  Methods Find Exp Clin Pharmacol       Date:  1984-08

9.  Enhancement of host resistance against virus infections by MTP-PE, a synthetic lipophilic muramyl peptide--I. Increased survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs.

Authors:  F M Dietrich; H K Hochkeppel; B Lukas
Journal:  Int J Immunopharmacol       Date:  1986

10.  The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide.

Authors:  Z Xu; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968
View more
  1 in total

1.  Roles of peripheral leukocytes and tissue macrophages in antibacterial resistance induced by free or liposome-encapsulated muramyl tripeptide phosphatidylethanolamide.

Authors:  P M Melissen; W van Vianen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.